DelveInsight’s Non-Hodgkin Lymphoma pipeline report depicts a robust space with 200+ Non-Hodgkin Lymphoma companies working ...

Detailed Analysis Into the Regulatory Landscape, Patent Landscape, Key Trends, Clinical Trails, Pricing Analysis, Market Dynamics and MoreDublin, May 06, 2025 (GLOBE NEWSWIRE) -- The "Adult T-Cell ...

Cheyney, PA, May, 5 2025 - Navrogen, Inc., a biopharmaceutical company specialized in developing antibody-based therapies for ...

When my friends asked if I was OK, I told them it was beautiful and couldn’t believe I was experiencing it with them.

The Blink-182 co-founder recalled how he was diagnosed with cancer and opened up to The Chris Moyles Show about his gruelling ...

For those patients that do relapse, the prognosis is poor ... available to people newly diagnosed with diffuse large B-cell lymphoma,” commented Roche’s chief medical officer, Levi Garraway.

The transcriptional repressor B-cell lymphoma 6 (BCL6) plays a central role in the development and progression of various B-cell malignancies, particularly diffuse large B-cell lymphoma (DLBCL), where ...

For this latter group, the prognosis is very poor ... in the EU for Columvi in relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The importance of biosimilars only continues to grow ...

Patients with primary cutaneous B-cell lymphoma showed a higher risk of developing prostate and hematologic cancers in a ...